Atriva Therapeutics, a Tübingen, Germany-based biopharmaceutical company developing host-targeting antiviral therapies, held the first closing in its ongoing series A financing round.
The round was led by Meneldor and High-Tech Gründerfonds (HTGF) with participation from founders and management.
Led by Dr. Rainer Lichtenberger, co-founder and CEO, Atriva Therapeutics is a biopharmaceutical company which aims to develop new antiviral therapies against different respiratory viral infections. Its lead product ATR-002 is a first-in-class host-targeting agent, inhibiting viral replication in influenza and other respiratory infections, an area of high unmet medical need. Atriva owns five broad patent families with broad coverage related to the use of MEK inhibitors for anti-viral therapies and late expiry in 2038.
The company intends to use the funds to focus to prepare first-in-humans clinical testing of its lead product candidate ATR-002, to be started in 2019.
During 2018, Atriva Therapeutics completed preclinical development of ATR-002 and recently filed a request for scientific advice from a European regulatory authority to provide guidance on the executed preclinical development program and the planned ATR-002 Phase I study in healthy volunteers.
The company, which will secure additional series A funds for the Phase I and Phase II development of ATR-002 through proof of concept trials, is now advancing ATR-002 towards full clinical development, focusing on patients with influenza at high risk of developing complications.